Novel Agent Curbs Alzheimer's-Related Agitation
AXS-05, a combination of dextromethorphan and bupropion, led to a rapid and sustained improvement in agitation related to Alzheimer's disease in the phase 3 ACCORD trial.
Stay updated with breaking news from Geisinger Memory. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AXS-05, a combination of dextromethorphan and bupropion, led to a rapid and sustained improvement in agitation related to Alzheimer's disease in the phase 3 ACCORD trial.
With voices ringing out in the background, Sandi Lubrant was all smiles sharing how much it meant to bring the Singing Hills Chorus of Mankato, Minnesota, back together for a
A critical shortage of clinicians and front-line workers to support increasing numbers of Alzheimer’s patients is impacting dementia care, advocates say. It’s leaving families with limited options and raising concerns
With voices ringing out in the background, Sandi Lubrant was all smiles sharing how much it meant to bring the Singing Hills Chorus of Mankato, Minnesota, back together for a
Research shows social engagement can play an important role in slowing dementia progression and onset.